RAMAT GAN, Israel, Nov. 3, 2025 /PRNewswire/ — Pulsenmore Ltd. (TASE: PULS), a pioneer in home ultrasound solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization for the Pulsenmore ES, a home-use prenatal ultrasound platform that enables expectant mothers to perform guided scans at home interpreted by remote physicians.
